Drug Trial Radar · NCT05338931
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Last checked: Nov 19, 2026Latest source record: May 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
82
Planned (sponsor's estimate)
Start
Mar 15, 2022
Primary completion
Mar 15, 2030
Study completion Sep 15, 2030
Sponsor
- Lead sponsor
- AbClonIndustry
- Sponsor type
- Industry
- First posted
- Apr 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.
Conditions
- B-cell Non Hodgkin Lymphoma
Interventions
AT101(Anti-CD19 Chimeric Antigen Receptor T cell)Drug
Anti-CD19 Chimeric Antigen Receptor T cell
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the maximum tolerant dose (MTD) and Recommended Phase 2 Dose (RP2D)Time frame: 28 days
- Overall response rate (ORR) by Independent assessmentTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.